Altre lingue Nirvana Life Sciences Inc.

Azioni

NIRV

CA6546521064

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 15:30:00 04/07/2024			Variaz. 5gg	Var. 1 gen.
0,01 ^CAD	0,00%		0,00%	-50,00%

02/04	Nirvana Life Sciences Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 gennaio 2024	CI
02/01	Nirvana Life Sciences Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 31 ottobre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	02/04
Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction	29/01
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	02/01
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	01/11
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	28/10/23
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc.	31/07/23
Nirvana Life Sciences Inc. entered into a letter of intent to acquire Medsmart Dispensary Inc. for $0.13 million.	07/06/23
Nirvana Life Sciences Inc. announced that it has received funding	10/05/23
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	03/04/23
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors	22/02/23
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	31/12/22
Nirvana Life Sciences Agrees to Buy Licensed Distributor of Patented, Herbal Treatment for Opiate Addiction	21/11/22
Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction	21/11/22
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors	09/11/22
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022	29/09/22
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives	22/09/22
Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds	07/09/22
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds	07/09/22
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	29/08/22
Nirvana Life Sciences Inc. Announces Executive Changes	09/08/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nirvana Life Sciences Inc.

Azioni

NIRV

CA6546521064

Altre lingue

Filtri